[company_age]unknown[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]Tacalyx GmbH is a German biotechnology company founded in 2019 that develops novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs). The company was spun out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany. Tacalyx's pipeline comprises several first-in-class assets targeting different TACAs across multiple solid human cancers. The company's assets are amenable to various treatment modalities, including antibody-drug conjugates, T cell engagers, and others. Tacalyx is headquartered in Berlin, Germany.[/description][ps]Novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs).[/ps]